

Maternal colonization with *Streptococcus agalactiae* and associated stillbirth and neonatal disease in coastal Kenya

Anna C. Seale^{1,2*}, Angela C. Koech², Anna E. Sheppard³, Hellen C. Barsosio², Joyce Langat², Emily Anyango², Stella Mwakio², Salim Mwarumba², Susan C. Morpeth^{2,4}, Kirimi Anampiu², Alison Vaughan³, Adam Giess³, Polycarp Mogeni², Leahbell Walusuna², Hope Mwangudzah², Doris Mwanzui⁵, Mariam Salim⁵, Bryn Kemp^{2,6}, Caroline Jones^{1,2,4}, Neema Mturi², Benjamin Tsofa², Edward Mumbo⁷, David Mulewa⁷, Victor Bandika⁸, Musimbi Soita⁹, Maureen Owiti⁵, Norris Onzere⁵, A. Sarah Walker³, Stephanie J. Schrag¹⁰, Stephen H. Kennedy⁶, Greg Fegan^{1,2}, Derrick W. Crook³ and James A. Berkley^{1,2}

***Streptococcus agalactiae* (group B streptococcus, GBS) causes neonatal disease and stillbirth, but its burden in sub-Saharan Africa is uncertain. We assessed maternal recto-vaginal GBS colonization (7,967 women), stillbirth and neonatal disease. Whole-genome sequencing was used to determine serotypes, sequence types and phylogeny. We found low maternal GBS colonization prevalence (934/7,967, 12%), but comparatively high incidence of GBS-associated stillbirth and early onset neonatal disease (EOD) in hospital (0.91 (0.25–2.3)/1,000 births and 0.76 (0.25–1.77)/1,000 live births, respectively). However, using a population denominator, EOD incidence was considerably reduced (0.13 (0.07–0.21)/1,000 live births). Treated cases of EOD had very high case fatality (17/36, 47%), especially within 24 h of birth, making under-ascertainment of community-born cases highly likely, both here and in similar facility-based studies. Maternal GBS colonization was less common in women with low socio-economic status, HIV infection and undernutrition, but when GBS-colonized, they were more probably colonized by the most virulent clone, CC17. CC17 accounted for 267/915 (29%) of maternal colonizing (265/267 (99%) serotype III; 2/267 (0.7%) serotype IV) and 51/73 (70%) of neonatal disease cases (all serotype III). Trivalent (Ia/II/III) and pentavalent (Ia/Ib/II/III/V) vaccines would cover 71/73 (97%) and 72/73 (99%) of disease-causing serotypes, respectively. Serotype IV should be considered for inclusion, with evidence of capsular switching in CC17 strains.**

One-half of all child deaths (<5 years) worldwide are in sub-Saharan Africa (sSA)¹ and one-third of these deaths occur in the neonatal period, from infection, preterm birth and neonatal encephalopathy¹. Stillbirths probably equal neonatal deaths in number, and infections are a major contributor². *Streptococcus agalactiae* (group B streptococcus, GBS) causes neonatal early and late onset disease (EOD, LOD), stillbirth³ and possibly contributes to preterm birth⁴ and neonatal encephalopathy⁵, as a consequence of ascending maternal genito-urinary colonization (for definitions see Supplementary Table 1). GBS emerged as the leading cause of EOD in the USA in the 1960s⁶ and subsequently in Europe, but in sSA there are outstanding major questions as to whether GBS commonly colonizes pregnant women, causes stillbirth, or is an important cause of neonatal disease. Establishing this is essential to informing potential preventive interventions. In resource-rich countries, reductions in EOD have followed the introduction of maternal microbiological or risk factor screening with

intra-partum antibiotic prophylaxis (IAP)⁷. However, there is uncertainty as to the feasibility of this approach in resource-poor settings, and there is no evidence of the effectiveness of IAP in preventing GBS-associated stillbirth, or LOD. Antisepsis at delivery has been shown to be ineffective⁸. However, maternal vaccination may provide a feasible strategy to reduce GBS disease in resource-poor countries. A trivalent conjugate vaccine (serotypes Ia/Ib/III) has completed phase 2 clinical trials⁹, and a pentavalent vaccine is in development¹⁰.

Understanding which women are most likely to be GBS colonized could provide insight into both the emergence of GBS and variation in the reported prevalence of maternal GBS colonization: Europe/USA 5–40% (refs 11,12); Africa 9–47% (Supplementary Table 2). Reported maternal risk factors for colonization are conflicting, with increased maternal GBS colonization reported in both younger¹³ and older¹⁴ age groups, African-American mothers^{13–15} and those with higher education^{14,16}, higher income¹⁶,

¹Nuffield Department of Medicine, Centre for Tropical Medicine and Global Health, University of Oxford, Oxford OX3 7FZ, UK. ²KEMRI-Wellcome Trust Research Programme, Kilifi 80108, Kenya. ³Modernizing Medical Microbiology Consortium, Nuffield Department of Medicine, University of Oxford, Oxford OX3 9DU, UK. ⁴London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK. ⁵Maternity Department, Kilifi County Hospital, Main Hospital Road, Kilifi 80108, Kenya. ⁶Nuffield Department of Obstetrics and Gynaecology, University of Oxford, Oxford, OX3 9DU, UK. ⁷County Ministry of Health, Kilifi County Hospital, Main Hospital Road, Kilifi 80108, Kenya. ⁸Department of Paediatrics, Coast Provincial General Hospital, Mombasa 80100, Kenya. ⁹Department of Obstetrics and Gynaecology, Coast Provincial General Hospital, Mombasa 80100, Kenya. ¹⁰Division of Bacterial Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, Georgia, 30333, USA. *e-mail: anna.seale@gmail.com




Figure 1 | Study design and recruitment of participants by study site. a, Recruitment timeline and sub-studies undertaken at each study site. **b**, Recruitment of mothers into the cohort study. *The denominator for live births in the prospective cohort period, used to calculate incidence of early onset disease (EOD) in KCH excluded those who did not deliver or had a stillbirth (leaving 6,598). **These mothers (7,967) were included in the analysis of risk factors for maternal GBS colonization. [§]These births (7,833) were included in analyses assessing GBS as a risk factor for stillbirth or perinatal death. ^{§§}These live births (7,408) were included in analyses assessing GBS as a risk factor for preterm birth, low birthweight or possible serious bacterial infection. **c**, Recruitment for the vertical transmission study (maternal–neonatal dyads), a subset of mothers who delivered in KCH. **d**, Recruitment for stillbirth nested case-control study including mothers who delivered in KCH and had a stillbirth, and controls.

high sexual activity¹⁴ and obesity^{15,16}. Data from sSA are limited, but are also conflicting for potentially important risk factors such as HIV infection. In South Africa, maternal GBS colonization was lower in HIV-infected mothers¹⁷, but in Malawi, only amongst HIV-infected mothers with lower CD4 counts¹⁸. In the USA¹⁵ and Zimbabwe¹⁹, no association with HIV was found. The limited data from studies in Kenya, Zimbabwe, Malawi and South Africa on colonizing maternal serotypes in sSA suggest serotype III is the most common (serotypes Ia/Ib/II/IV/V are also reported)^{18,20–22}.

For neonatal disease, data outside the USA and Europe are sparse²³. In sSA, facility-based studies generally report a high incidence of neonatal GBS disease, but population-based and outpatient studies have reported much lower incidences^{24,25}, including what was described as a ‘striking absence’ of invasive neonatal GBS disease in large outpatient-based studies²⁴. However, regional estimates, which included only four studies from Africa (one of which is our study site in Kilifi County)^{8,26–28}, suggest that Africa may have the highest regional burden of neonatal GBS disease at 1.2 (0.50–1.91)/1,000 live births²³. These limited data suggest that serotype III, as described in other regions²³, most commonly causes disease, with rates for EOD and LOD of 52 and 72% in Malawi and 49 and 76% in South Africa; serotypes Ia/Ib/II/V are also reported^{27,29}. The incidence of GBS-associated stillbirth is unknown in sSA³,

with data from only two studies (one found no GBS-associated stillbirth³⁰, and the other reported GBS-associated stillbirth in 8/66 (12%) stillbirths³¹).

The population structure of GBS in Europe and the USA can be described by five major clonal complexes: CC1, CC10, CC17, CC19 and CC23 (refs 32,33), with CC17 overrepresented in disease isolates^{32,34}. These five clonal complexes are also found in Africa³². In addition, CC26 is common in some regions, representing 15% of sampled GBS isolates in Dakar and Bangui³⁵. GBS also causes bovine mastitis, which is largely mediated by the bovine-specific CC67, although the five major human clonal complexes can also be found in cattle^{33,36,37}.

In this study, we aimed to comprehensively describe the clinical epidemiology of maternal GBS colonization, neonatal disease and stillbirth in coastal Kenya, with molecular analysis to determine the associated serotypes, sequence types (STs) and phylogeny.

Results

Maternal GBS colonization and adverse perinatal outcomes. During the study, 10,130 pregnant women attended a health facility and we recruited 7,967 (Fig. 1, sample size Supplementary Table 3). Of these, 526/7,967 (6.6%) were from rural sites, 5,470/7,967 (68.7%) were from semi-rural locations and 1,971/7,967

Table 1 | Exposures associated with maternal GBS colonization.

Variable	No GBS*			Complete cases (N = 3,979)			Imputed data (N = 7,967)		
	N not missing	GBS* N not missing	(%)	OR	95%CI [†]	P [‡]	OR	95%CI [†]	P [‡]
Site									
Rural	479	47	(8.9)	0.80	(0.73–0.88)	<0.001	0.91	(0.88–0.94)	<0.001
Semi-rural	4,862	608	(11.1)	1			1		
Urban	1,692	279	(14.2)	0.96	(0.93–1.00)		0.95	(0.92–0.98)	
Age in quartiles (years)[§]									
<21.5	1,674	166	(9.0)	0.77	(0.55–1.15)	0.009	0.80	(0.57–1.15)	0.023
21.5–25.3	1,663	223	(11.8)	1.15	(0.87–1.22)		1.03	(0.88–1.22)	
25.4–29.9	1,656	213	(11.4)	1			1		
≥30	1,672	186	(10.0)	0.91	(0.78–1.18)		0.96	(0.79–1.18)	
Parity									
0	2,986	365	(10.9)	1.06	(0.99–1.09)	<0.001	1.05	(1.00–1.10)	<0.001
1–4	3,550	442	(11.1)	1			1		
≥5	1,341	119	(8.2)	0.85	(0.69–0.92)		0.81	(0.70–0.93)	
Ethnicity: Mijikenda									
No	2,226	345	(13.4)	1		0.002	1		0.003
Yes	5,617	578	(9.3)	0.65	(0.60–0.90)		0.73	(0.59–0.90)	
Household socio-economic status (quartiles)[§]									
Very low	1,086	96	(8.1)	0.88	(0.66–1.16)	<0.001	0.89	(0.66–1.19)	<0.001
Low	2,720	294	(9.8)	1			1		
Medium	2,123	229	(9.7)	1.00	(0.82–0.92)		0.88	(0.82–0.93)	
High	2,038	315	(13.4)	1.24	(1.06–1.30)		1.21	(1.13–1.29)	
Mother looks after cattle									
No	7,471	873	(10.5)	1		<0.001	1		<0.001
Yes	449	56	(11.1)	1.46	(1.17–1.42)		1.29	(1.17–1.43)	
Nutritional status (mid-upper arm circumference in cm[§])									
≤23.9	1,428	125	(8.0)	0.77	(0.60–0.89)	<0.001	0.72	(0.60–0.88)	<0.001
24–25.9	2,219	264	(10.6)	1			1		
26–27.9	1,662	183	(9.9)	0.80	(0.66–1.07)		0.85	(0.67–1.08)	
≥28	2,170	309	(12.5)	1.02	(0.78–1.40)		1.05	(0.79–1.42)	
HIV infection									
No	7,285	879	(10.8)	1		<0.001	1		<0.001
Yes, no CTX [¶]	239	20	(7.7)	1.16	(0.92–1.45)		0.68	(0.42–1.09)	
Yes, on CTX [¶]	161	5	(3.0)	0.20	(0.14–0.26)		0.24	(0.14–0.39)	
Vaginal examination before swab									
No	4,952	609	(11.0)	1		0.019	1		0.057
Yes	780	73	(8.6)	0.57	(0.36–0.91)		0.83	(0.70–1.00)	
Obstetric complication									
No	6,913	823	(10.6)	1		<0.001	1		<0.001
Yes	1,054	111	(9.5)	0.78	(0.70–0.88)		0.85	(0.79–0.92)	

*Full details on all variables and numbers for missing variables are given in Supplementary Table 4; [†]95% confidence intervals are given, based on robust standard errors to account for intracluster correlation within recruitment sites; [‡]P values are derived from the Wald test (imputations combined using Rubin's rules); [§]For continuous variables we tested for associations prior to categorization and inclusion in the model. Where there was nonlinearity, natural cubic splines were used (Supplementary Fig. 2). Data were categorized for ease of presentation and the largest group was used as the reference group; ^{||}Mijikenda are the indigenous coastal population; [¶]CTX, co-trimoxazole prophylaxis.

(24.7%) were from an urban site. There were some differences in demographics in those excluded (Supplementary Table 4), with emergency referrals more likely to be excluded, as well as women with incomplete data on age, ethnicity or parity, although overall numbers were small. Transport times to the laboratory were longer from urban and rural sites (median 11 h (range 0–48 h); 11 h (0–52 h)) compared to semi-rural locations (5 h (0–73 h), but there was no evidence of association between GBS isolation and time to sample processing across all sites (odds ratio (OR) = 1.00 (0.99–1.00), $P = 0.6$), across rural and urban sites (OR = 0.99 (0.98–1.00)), or each site individually (Supplementary Fig. 1).

Overall, 934 (11.7% (11.0–12.5%)) women were GBS-colonized at delivery. Prevalence was lowest at rural sites (47/526, 8.9% (6.6–11.7%)), intermediate at semi-rural sites (608/5,470, 11.1% (10.2–12.0%)) and highest at the urban site (279/1,971, 14.2% (12.6–15.8%); trend $P < 0.001$). However, after adjustment for other risk factors (including maternal age, socio-economic status and ethnicity; univariable analyses, Supplementary Table 5), the odds of isolating GBS at the urban site (OR = 0.95 (0.92–0.98)) and rural site (OR = 0.91 (0.88–0.94)) were lower than at the semi-rural site ($P < 0.001$; Table 1).

GBS colonization was independently associated with maternal age, highest in the middle categories (Supplementary Fig. 2; $P = 0.023$). It was also associated with parity (≥5 versus 1–4) (OR = 0.81 (0.70–0.93), $P < 0.001$), as well as Mijikenda ethnicity (indigenous population, OR = 0.73 (0.59–0.90), $P = 0.003$) (Table 1). GBS colonization was increased in women with higher socio-economic status (OR = 1.21 (1.13–1.29), $P < 0.001$) and those who had contact with cattle (OR = 1.29 (1.17–1.43), $P < 0.001$). GBS colonization was reduced among HIV-infected women and especially in HIV-infected women taking co-trimoxazole prophylaxis (OR = 0.68 (0.42–1.09); OR = 0.24 (0.14–0.39), $P < 0.001$), in less well-nourished mothers (OR = 0.72 (0.60–0.88), $P < 0.001$) and in women with obstetric emergencies (OR = 0.85 (0.79–0.92), $P < 0.001$).

There was evidence that adverse perinatal outcomes (very preterm delivery, very low birthweight, stillbirth, possible serious bacterial infection; for definitions see Supplementary Table 1) were associated with maternal GBS colonization in multivariable models in the context of interactions with clinical risk factors for invasive GBS disease, such as maternal temperature $>37.5^{\circ}\text{C}$, urinary tract infection and prolonged rupture of membranes >18 h (Fig. 2 and Supplementary Tables 6–9). In contrast, without




Figure 2 | Interaction of risk factors at delivery with maternal GBS colonization associated with adverse newborn outcomes. Interactions between maternal risk factors at delivery (maternal fever, maternal urinary tract infection, prolonged rupture of membranes) and adverse perinatal outcomes (very preterm birth, very low birthweight, stillbirth, possible serious bacterial infection), in the presence and absence of maternal GBS colonization. Odds ratios are given for maternal exposures and associated perinatal outcome (listed vertically) with 95% confidence intervals illustrated with error bars for the odds ratio in each case. Interactions were included in multivariable models if there was evidence of interaction at the $P < 0.1$ level in univariable analyses. P values given here are for interaction tests in imputed multivariable models (details for all models are provided in Supplementary Tables 5–9). **Possible serious bacterial infection (pSBI) is defined in Supplementary Table 1; this is a clinical diagnosis used to guide empiric treatment of neonates for possible serious bacterial infections in resource-poor settings.

GBS colonization there was no evidence that these clinical factors conferred elevated risk of poor outcomes. There was no evidence of association of maternal GBS colonization with perinatal mortality ($P = 0.7$; Supplementary Table 10), including testing for an interaction with any risk factor for GBS disease ($P = 0.4$).

Of 918/934 (98.3%) available and extracted colonizing isolates, 915/934 (98.0%) were of sufficient quality for genomic analysis. Among colonized mothers, 658/915 (71.9%) GBS isolates were serotypes Ia, Ib or III, with serotype III being most common (350/915 (38.3%)). Clonal-complex 17 (CC17) was identified in 267/915 (29.2%) of GBS-colonized women (Figs 3 and 4 and Supplementary Table 11). Of these, 265/267 (99.3%) were serotype III and 2/267 (0.7%) were serotype IV.

The population structure was broadly similar to that in other parts of the world, with 114/915 (12.5%) CC1, 148/915 (16.2%) CC10, 268/915 (29.3%) CC17, 173/915 (18.9%) CC19, 208/915 (22.7%) CC23, with 4/915 (0.4%) not belonging to any commonly described clonal complex. No bovine-associated CC67 (ref. 38) GBS isolates were identified. Each of the five major clonal complexes was represented at each site (Fig. 4 and Supplementary Table 12), with no evidence for geographic stratification. Within the clonal complexes, there was considerable diversity, with a total of 43 distinct STs, 18 of which were newly identified in this study. The largest number of STs was seen in CC17 (12 STs in total, with 8 newly identified). The most common STs within CC17 were ST17 (183/268, 68.3%) and ST484 (67/268, 25.0%).

Within GBS-colonized women, risk factors for colonization with the most virulent clone, CC17, were, in general, the reverse of those associated with GBS colonization overall (Table 2). Maternal GBS CC17 was increased in rural sites (OR = 1.26 (1.20–1.31), $P < 0.001$), in women of Mijikenda ethnicity (OR = 1.62 (1.43–1.85), $P < 0.001$) and in women with HIV infection and women with HIV infection taking co-trimoxazole (OR = 1.46 (1.11–1.92) and OR = 4.30 (0.59–31.3), $P < 0.001$). Mothers who had contact with cattle (OR = 0.54 (0.45–0.64), $P < 0.001$) and were better nourished (OR = 0.79 (0.42–1.49), $P < 0.001$) were less frequently colonized with CC17,

but this did not hold for ST17 (Supplementary Table 13). For each of the risk factors, including cattle contact, the corresponding isolates were dispersed in the phylogeny (Fig. 4), suggesting that the associations were not driven by specific sublineages.

Pairwise comparison of all maternal colonizing isolates in mothers delivering at Kilifi County Hospital (KCH) showed increased genetic similarity in a small number of mothers who delivered within seven days of one another, but not according to household location (Supplementary Fig. 3). Of mothers admitted fewer than seven days apart in KCH, there were 14/1,013 (1.4%) pairs from mothers admitted on the same day with 0–4 single nucleotide variant (SNV) differences, 11/1,967 (0.6%) one day apart, 2/1,845 (0.1%) two days apart and 2/1,832 (0.1%) six days apart ($P < 0.001$). At rural sites, among mothers admitted fewer than seven days apart, there were 2/124 (1.6%) pairs from mothers admitted on the same day with 0–4 SNV differences and 2/219 (0.9%) from those admitted one day apart ($P = 0.1$). At the urban site, there were 8/987 (0.8%) pairs from mothers admitted on the same day with 0–4 SNV differences and 3/1,555 (0.2%) from those admitted one day apart ($P < 0.001$)²².

GBS in mother–neonatal pairs (surface contamination). We recruited 830 mother and baby pairs at KCH (Fig. 1 and Supplementary Table 14). Of these, 104/830 (12.5% (10.4–15.0%)) mothers were colonized with GBS at delivery, and 44/830 (5.3% (3.9–7.1%)) neonates had GBS isolated from ear, umbilicus or nose within 6 h of delivery. A total of 30/44 (68.2%) neonates with surface GBS were born to one of the 104 GBS-colonized mothers, and 14/44 (31.8%) were born to one of the 726 mothers without colonizing GBS detected (of these, 2/14 (14.3%) were born by caesarean section). Odds of neonatal surface GBS were high with maternal GBS colonization (OR = 20.6 (10.5–40.6), $P < 0.001$).

Pairwise SNV comparisons between maternal and newborn isolates showed a clear bimodal distribution: 26/30 (86.7%) pairs differed by ≤ 4 SNVs (all pairs the same ST and serotype), presumably representing vertical transmission, and 4/30 (13.3%)




Figure 3 | GBS types colonizing mothers and causing disease. **a**, Invasive neonatal GBS disease cases decrease after the first few days of birth in KCH neonatal admissions (1998–2013) and serotype III causes an increasing proportion of disease. **b**, The clinical infection syndrome is predominantly sepsis in the first few days after birth in neonates admitted with invasive GBS disease to KCH (1998–2013), with increasing numbers of neonates admitted with meningitis with or without sepsis later in the neonatal period. **c**, Percentage of different serotypes in GBS isolates from maternal colonization, early onset disease (EOD) and late onset disease (LOD) in neonates shows a stepwise increase in serotype III from maternal colonization to EOD and LOD. **d**, Percentage of different clonal complexes in GBS isolates from maternal colonization, neonatal sepsis and neonatal meningitis (+/– sepsis) shows the increasing dominance of CC17 in neonatal disease, particularly in neonatal meningitis.

pairs were highly divergent (>9,000 SNVs, with different STs and different serotypes) (Fig. 4). Combining all pairs with ≤ 4 SNVs, the SNVs were dispersed throughout the genome, with no gene represented more than once. There were 7/44 (15.9%) neonates with surface GBS after delivery by caesarean section (5 of their mothers had GBS detected; 3/5 had 0 SNV differences, 1/5 had 1 SNV and 1/5 had 9,673 SNVs).

Stillbirth. There were 278 stillbirths during the nested case-control study (278/4,394 (6.3%) all births). We sampled cord blood in 149/278 (53.6%; 94/149 (63.1%) intra-partum, 55/149 (36.9%) ante-partum stillbirths), 104 also had a lung aspirate, and 34/278 (12.2%) had a lung aspirate sample only. In total, 183/278 (65.8%) stillbirths were sampled, plus 330 live-birth cord blood controls (Fig. 1).

GBS was isolated from 4/183 (2.2% (95%CI 0.6–5.5)) stillbirths (3/149 cord blood samples, 2/138 lung aspirates; one stillbirth had GBS isolated from both), two ante-partum (36 and 39 weeks gestation) and two intra-partum (35 and 39 weeks). The overall minimum incidence of GBS-associated stillbirth (cord blood or lung aspirate) was 0.91 (0.3–2.3)/1,000 births. Compared to live-born controls (GBS isolated from 1/330 (0.3%)), GBS was isolated more frequently from cord blood in stillbirths (OR = 6.8 (0.7–65.5), $P = 0.09$) and, in a multinomial model, ante-partum stillbirths (OR = 12.4 (1.1–139.3)) and intra-partum stillbirths (OR = 3.5 (0.2–57.1) exact $P = 0.055$). Serotype data were available from three stillbirths (two were serotype V and one serotype III).

There were 2/4 GBS-associated stillbirths born to GBS colonized mothers (2/2 pairs differed by 0 SNVs, all ST1, serotype V). One mother was not colonized, and one was not tested. The risk ratio for GBS-associated stillbirth in GBS-colonized versus non-colonized mothers was 7.6 (1.1–52.6, $P = 0.016$).

Neonatal disease. Eighty-two neonates with invasive GBS disease were admitted to KCH (1998–2013, Fig. 1), of which 36/82 (43.9%) and 43/82 (52.4%) were associated with EOD and LOD, respectively (three unknown). Case fatality was highest in EOD (17/36 (47.2%)), despite treatment, particularly for those diagnosed within <24 h of birth (11/18 (61.1%)). In patients with LOD, 5/43 (11.6%) died. Most GBS EOD cases (52/82 (63.4%)) were male and 25/82 (30.5%) weighed <2,500 g at admission (Supplementary Table 15). Sepsis without focus was predominant in EOD (33/36 (91.6%)), with meningitis (+/– sepsis) being more common in LOD (21/43 (48.8%)) (Fig. 3). Gestational age was not routinely available from previous clinical surveillance data, but there were five EOD cases with gestations of 36, 36, 37, 37 and 40 weeks born at the time of the prospective cohort study (versus a median of 38 (interquartile range (IQR) 36–40) overall in the prospective cohort).

EOD incidence among deliveries at KCH during the cohort study (2011–2013) was 0.76 (0.25–1.77)/1,000 live births. Including only residents in the Kilifi Health and Demographic Surveillance System (KHDSS) population (1998–2013), the (minimum) population-based incidence of neonatal GBS disease was 0.34




Figure 4 | Phylogenetic reconstructions of GBS isolates. Maximum likelihood phylogenies, with recombinant regions removed, are shown separately for each clonal complex. Background shading indicates ST17 isolates within CC17. Serotypes are illustrated for each clonal complex in the innermost circle. The next circle describes the sample source of the GBS isolate (neonatal invasive or maternal colonizing, by site of recruitment). For maternal colonizing isolates, epidemiological details are presented. From the outermost circle these are maternal HIV status (negative, HIV-infected, HIV infected and taking prophylactic co-trimoxazole), socio-economic status (high, medium, low and very low), ethnicity (Mijikenda or non-Mijikenda) and the presence or absence of cattle contact.

(0.24–0.46)/1,000 live births: EOD in 0.13 (0.07–0.21)/1,000 live births and LOD in 0.21 (0.14–0.31)/1,000 live births, with no evidence of a trend over the study period (Supplementary Fig. 4).

There were 73/82 (89.0%) neonates with available invasive isolates that were extracted, and all were of sufficient quality for inclusion in the final analysis. Serotypes Ia/Ib/III caused 71/73 (97.3%) of EOD and LOD, and serotypes Ia/Ib/II/III caused 72/73 (98.6%) of cases. Serotype III predominated in both EOD (18/30 (60.0%)) and LOD (36/40 (90.0%); $P=0.003$, χ^2 test for trend). These isolates were all CC17, except one CC19 isolate (Fig. 4). Serotype III was the almost universal cause of meningitis (22/23 (95.7%) cases), of which 21/22 (95.4%) were CC17 (Fig. 3 and Supplementary Table 16). Isolates were all susceptible to penicillin and 61/76 (80.3%) were susceptible to co-trimoxazole.

Three of the five neonates with EOD born at KCH (2011–2013) were born to GBS-colonized mothers (1/3 pairs differed by 0 SNVs (both ST17, serotype III), 1/3 pairs by 88 SNVs (one ST17, one ST484, both serotype III) and 1/3 pairs by 1,002 SNVs (both ST17, serotype III), with a risk ratio (RR) for EOD for GBS-colonized versus non-colonized mothers of 11.8 (2.0–70.3), $P<0.001$). For all perinatal GBS disease (EOD or stillbirth), $RR=13.1$ (3.1–54.8, $P<0.001$).

Discussion

GBS is an important cause of stillbirth and neonatal disease in Kenya. The incidence of stillbirth was comparable to EOD in hospital births (0.91 (0.25–2.3)/1,000 births and 0.76 (0.25–1.77)/1,000

live births, respectively). These incidences are all underestimates, with samples not taken from all stillbirths and insensitivity in cultures, particularly if intrapartum antibiotics were given. The much lower population-based incidence of EOD (0.13 (0.07–0.21)/1,000 live births) suggests recruitment bias with under ascertainment of cases in the community, or in outpatient settings, due to rapid case fatality after delivery and limited access to care. This is supported by the higher proportion of LOD, which is the reverse of the ratio of GBS disease typically seen in high-income countries²³. Although it could be argued that facility delivery is a risk factor for EOD (if there was in-hospital maternal GBS acquisition), we found very limited evidence of horizontal transmission in facilities, with few genetically near-identical pairs (0–4 SNVs, threshold determined empirically from a newborn surface contamination study) in mothers admitted fewer than seven days of each other.

However, there may be true differences in the incidences of both GBS-associated stillbirth and neonatal GBS disease in sSA, which are neither explained by the study design nor by other methodological limitations. The incidences of neonatal GBS disease recently reported in urban South Africa²⁹ and Malawi²³ are high and could be due to differences in maternal GBS colonization prevalence, consistent with our finding of a higher prevalence of maternal GBS colonization in urban compared to semi-rural and rural residents. This association was explained by variables describing an improved socio-economic status and other factors associated with improved health, such as better nutritional status, being in middle age categories and a lower parity, both in the complete-case analyses and

Table 2 | Exposures associated with maternal GBS colonization with CC17.

Variable	GBS			Univariable complete cases (N = 914)			Multivariable complete cases (N = 728)		
	Not CC17	N CC17	(%)	OR	95%CI*	P [†]	OR	95%CI*	P [†]
Site									
Rural	33	13	28.3	0.85	(0.43-1.65)	0.072	1.26	(1.20-1.31)	<0.001
Semi-rural	403	187	31.7	1			1		
Urban	211	67	24.1	0.68	(0.49-0.95)		0.98	(0.79-1.04)	
Age in quartiles (years)[‡]									
<21.5	115	49	29.9	1.16	(1.07-1.27)	0.2	1.21	(0.88-1.67)	0.004
21.5-25.3	156	60	27.8	1.05	(0.92-1.21)		0.88	(0.77-1.01)	
25.4-29.9	153	56	26.8	1			1		
≥30	130	51	28.2	1.07	(0.85-1.35)		1.06	(0.74-1.51)	
Parity									
0	257	98	27.6	0.86	(0.49-1.51)	0.4	0.75	(0.35-1.55)	<0.001
1 to 5	301	133	30.6	1			1		
≥5	83	35	29.7	0.95	(0.83-1.10)		0.68	(0.60-0.80)	
Ethnicity: Mijikenda[§]									
No	262	79	23.2	1		<0.001	1		<0.001
Yes	379	183	32.6	1.60	(1.52-1.69)		1.62	(1.43-1.85)	
Household socio-economic status[‡] (quartiles)									
Very low	71	25	26.0	0.61	(0.48-0.80)	<0.001			
Low	192	95	33.1	1					
Medium	155	69	30.8	1.21	(0.82-1.80)				
High	229	78	25.4	0.69	(0.41-1.15)				
Mother looks after cattle									
No	598	255	29.9	1		<0.001	1		<0.001
Yes	44	12	21.4	0.64	(0.58-0.70)		0.54	(0.45-0.64)	
Nutritional status (mid-upper arm circumference in cm[‡])									
≤23.9	81	41	33.6	1.19	(0.57-2.56)	0.0042	1.05	(0.39-2.83)	<0.001
24-25.9	181	77	29.8	1			1		
26-27.9	130	48	27.0	0.87	(0.56-1.35)		0.73	(0.42-1.28)	
≥28	219	85	28.0	0.91	(0.57-1.46)		0.79	(0.42-1.49)	
HIV infection									
No	608	251	29.2	1		<0.001	1		<0.001
Yes, no CTX	13	7	35.0	1.30	(1.21-1.40)		1.46	(1.11-1.92)	
Yes, on CTX	2	3	60.0	3.63	(1.58-8.34)		4.30	(0.59-31.3)	

*95% confidence intervals are given, based on robust standard errors to account for intracluster correlation within recruitment sites; [†]P values are derived from the Wald test; [‡]For continuous variables we tested for associations prior to categorization and inclusion in the model. Where there was nonlinearity, natural cubic splines were used (Supplementary Fig. 2). Data were categorized for ease of presentation and the largest group was used as the reference group; [§]Mijikenda are the indigenous coastal population; ^{||}CTX, co-trimoxazole prophylaxis.

using multiple imputation. Although our study includes impoverished populations, the pattern of risk factors identified is consistent with recent studies in high-income countries reporting increased maternal GBS colonization with higher education^{14,16} and higher income¹⁶. The reasons for this are unclear, but are probably related to changes in the maternal microbiome, with different community states reported³⁹.

The use of prophylactic co-trimoxazole among HIV-infected women had a clear negative association with GBS colonization. Previously reported conflicting findings^{17,18} may depend on the frequency of antimicrobial use (and provision of anti-retroviral therapy). In contrast, neonatal GBS disease is increased with HIV exposure⁴⁰, with reduced maternal GBS capsular antibody in HIV-1 infection^{41,42} and/or because, as shown here, the most virulent clone, CC17, is more frequently found in HIV-infected GBS colonized women, compared to other non-CC17 types. A number of virulence factors (adhesins, invasins and immune evasins) have been associated with an increased ability of GBS to colonize and cause disease⁴³, with the more homogeneous CC17 having acquired its own set of virulence genes³⁸ and increased ability to form biofilms in acidic conditions⁴⁴.

We observed an association between cattle contact and maternal GBS colonization, but no bovine-associated CC67 isolates were identified, and the isolates from women with cattle contact were from a variety of lineages representing all major CCs. Little is known about bovine GBS populations in Kenya, and it is possible that the human and bovine populations are similar, thus leading to the association between cattle contact and maternal GBS colonization

from genuine transmission, as suggested elsewhere⁴⁵. Alternatively, women who look after cattle may be of a higher socio-economic status, and thus the association could be due to residual confounding.

The overall GBS population structure outlined here is similar to that found in previous studies from a variety of geographic locations, supporting the notion of recent global dissemination of relatively few clones³². Within this study, we found no evidence for geographic clustering of related isolates, both at the level of sampling location (Fig. 4) and distance between households (Supplementary Fig. 3), further suggesting the rapid geographic dispersal of GBS. However, in contrast to a previous study from Africa³⁵, we found no CC26 isolates, suggesting that this lineage may be geographically restricted. Furthermore, we found a large number of ST484 isolates, 67/915 (7.3%) of the total and 67/268 (25.0%) of CC17. This lineage has previously been reported in only a single study, also from Kenya⁴⁶. We also identified three novel STs that represent single-locus variants of ST484. Taken together, it is possible that ST484 originated in or near Kenya, with relatively little geographic dispersal. Alternatively, there may be a lack of GBS sampling in other locations where ST484 is present.

Prevention strategies in resource-rich settings focus on reducing EOD through IAP using either microbiological or risk-factor screening to identify at-risk mothers⁷. Both strategies would be challenging in resource-poor settings. Of interest, when comparing these strategies, however, is the fact that associations with adverse perinatal outcomes were only detected through interactions between maternal GBS colonization and clinical risk factors. This supports a mechanism of action whereby colonizing maternal

GBS ascends, leading to chorioamnionitis (intra-amniotic infection) and fever in a small proportion of women, leading to poor perinatal outcomes. Neither maternal GBS colonization without signs of infection nor maternal fever without GBS colonization increased the risk of adverse perinatal outcomes. Thus, either approach (microbiological or risk-factor screening) will target far larger numbers than those actually at risk. Any direct association between maternal GBS colonization and adverse outcomes may also be diluted by the many other causes of adverse perinatal outcomes and by misclassification (for example, uncertainty over the date of the last menstrual period to determine gestation), which may explain some of the conflicts in findings of studies assessing the contribution of GBS to preterm birth⁴.

We demonstrated the vertical transmission of maternal GBS colonization in maternal–newborn dyads, for both surface contamination (including cases of emergency caesarean section) and perinatal disease. Genetically divergent maternal–newborn dyads may reflect unsampled variation in the mother, as only a single colony was sequenced in each case. Although adaptive mutations associated with disease progression have been reported elsewhere from a comparison of mother–newborn pairs⁴⁷, we were unable to find evidence for this in the current study, as all pairs involving invasive isolates were either genetically identical (0 SNVs) or divergent enough to argue against this. The findings show that GBS infection occurs before delivery, supporting the need for IAP to be administered before delivery to be effective and showing why antisepsis in active labour (for example, by using vaginal chlorhexidine wipes) is ineffective in reducing neonatal EOD⁸. The finding of 14/44 (31.8%) newborns with surface GBS contamination where maternal GBS colonization was not identified suggests insensitivity of maternal recto–vaginal screening, despite the consistent use of broth-enrichment and blood agar to maximize sensitivity. This is a higher percentage than found in a recent study in The Gambia (40/186 (21.5%))⁴⁸, but this study excluded mothers at high risk for pregnancy complications. As is found with repeat vaginal examinations, as seen here and reported elsewhere⁴⁹, complicated deliveries (obstetric emergencies) probably decrease GBS sampling sensitivity, through antisepsis measures or mechanical removal.

With limitations in the clinical benefit of IAP in terms of reducing stillbirth and LOD, as well as challenges in its effective implementation to reduce EOD in sSA, maternal vaccination is an attractive strategy for prevention. The most advanced vaccine (which has completed phase 2 trials) is trivalent (Ia/Ib/III), but plans exist to advance a pentavalent vaccine¹⁰. If this includes the most common disease-causing serotypes worldwide (Ia/Ib/II/III/V), it will cover almost all (72/73 (98.7%)) of the serotypes causing invasive disease in this study. However, importantly for vaccine development, and in line with other reports⁵⁰, we identified capsular switching to serotype IV in two isolates within CC17, suggesting that consideration of the inclusion of serotype IV is warranted.

GBS is an important, potentially preventable, cause of stillbirth and neonatal death in coastal Kenya. Maternal GBS colonization increases with urbanization and higher socio-economic status, and is likely to increase with development. GBS neonatal disease in population-based studies is markedly under-ascertained as a result of rapid case fatality after birth and limited access to care. The burden of early neonatal disease is likely equalled by the burden of GBS-associated stillbirth. Maternal GBS vaccination is a key opportunity to reduce stillbirth and neonatal death in this high-burden region.

Methods

Study design. The study design included a prospective cohort from rural, semi-rural and urban sites, a nested case–control study in the semi-rural site, and analysis of the surveillance of neonatal disease at the semi-rural site (Fig. 1).

Prospective cohort study. In a prospective cohort study (2011–2013), we assessed the prevalence and risk factors for maternal GBS colonization at delivery, and the

perinatal outcomes at delivery (stillbirth, gestational age, birthweight, possible serious bacterial infection and perinatal death).

Nested case–control study. The investigation of stillbirth was undertaken with a nested case–control study. Cord blood cultures were taken at delivery from the stillbirth and from the next two subsequent admissions that were live born (case: controls = 1:2). Lung aspirates were taken from stillbirths only, by a study clinician attending within 4 h of the stillbirth.

Surveillance of neonatal invasive bacterial disease. Neonatal disease was quantified using systematic clinical and microbiological surveillance data (1998–2013 at KCH) within the KHDSS area, giving accurate population and birth denominators (see ‘Study sites’)⁵¹.

Study sites. The studies were conducted at Coast Provincial General Hospital, Mombasa (CPGH; urban location, ~12,000 deliveries per year, comprehensive obstetric care); at Kilifi County Hospital (KCH; semi-rural, ~3,000 deliveries per year, comprehensive obstetric care); at Bamba sub-district hospital (rural, ~600 deliveries a year, basic obstetric care) and Ganze health facility (rural, ~400 deliveries a year, basic obstetric care).

Part of Kilifi County is included in detailed health and demographic surveillance (KHDSS)⁵¹, from which accurate population data are available from 2004. KCH is the main district hospital serving this population, so incidence estimates for residents seeking healthcare at KCH can be made with the KHDSS population as the denominator. We used prospectively collected data on live births from the regular re-enumerations of the KHDSS population, and used the estimated slope from a regression to estimate the number of births before the start of KHDSS.

Study population. Prospective cohort study. We included all women admitted for delivery at study sites at designated times who gave written informed consent, without additional exclusion criteria. We planned to recruit over one calendar year (to allow for seasonality), but extended the enrolment to meet sample size requirements (Supplementary Table 3) because national strikes closed government health facilities twice during the study. Recruitment was performed at CPGH for 48 h each week (1 April 2012 to 31 July 2013), at Bamba and Ganze for six days each week (1 July 2012 to 31 July 2013) and at KCH every day (1 August 2011 to 31 July 2013), including additional studies of neonatal surface contamination (1 May 2012 to 31 July 2013).

Nested case–control study. We included all stillbirths delivered in KCH and the next two consecutive live births (1 May 2012 to 1 October 2013).

Surveillance of neonatal invasive bacterial disease. We included all neonates admitted to KCH (1 August 1998 to 1 October 2013).

Sampling and laboratory methods. Prospective cohort study. We took recto–vaginal swabs during routine vaginal examination at admission for delivery, when possible before rupture of membranes. A small cotton swab was used to wipe the lower third of the vaginal mucosa and then the inside surface mucosa of the anus⁵², according to standard procedures. Neonatal surface swabs (to assess surface contamination) included the external ear, nares and umbilicus. Swabs were placed into Amies transport medium with charcoal⁵³, refrigerated, transported in cool containers⁵³ to the research laboratory (participating in the UK National External Quality Assessment Service) and processed by standard protocols (including enrichment (Lim broth) and subculture onto blood agar). Isolates with GBS morphology were Christie Atkins Munch–Peterson (CAMP) tested and definitive grouping done using a Streptococcal grouping latex agglutination kit (PRO-LAB Diagnostics).

Nested case–control study. For stillbirths and live-born controls, we sampled cord blood at delivery after double clamping the cord if necessary and cleaning with 70% ethanol. We processed cord blood cultures using an automated culture system (BACTEC 9050, Becton Dickinson). Lung aspirate samples (stillbirths only) were taken with a sterile technique by aspirating the lung within 4 h of delivery. We examined lung aspirates with microscopy and cultured using standard methods within 30 min of sampling, or if a delay was unavoidable they were stored at 2–8 °C for up to 8 h.

Surveillance of neonatal invasive bacterial disease. For all neonatal admissions (1998–2013) at KCH, peripheral blood was sampled on admission for culture, before neonatal antibiotic treatment (during 2011–2013, peri-partum maternal antibiotics were documented in 36/5,430 (0.7%) of deliveries in KCH), and we carried out lumbar puncture when clinically indicated. We tested the isolates for antimicrobial susceptibility to penicillin and co-trimoxazole (British Society for Antimicrobial Chemotherapy). Blood cultures were processed using an automated culture system (BACTEC 9050). Cerebrospinal fluid was tested as described elsewhere²⁶.

Molecular methods. DNA extraction, Illumina sequencing (HiSeq Technology) and raw read processing were carried out using standard methods starting from a

single GBS colony. GBS isolates were frozen in 1 ml vials and stored at -80°C before subculture on a Columbia blood agar plate for 24–48 h, followed by DNA extraction from a single colony using a commercial kit (QuickGene, Fujifilm). High-throughput sequencing was undertaken at the Wellcome Trust Centre for Human Genetics (Oxford University) using HiSeq2500, generating 150 base-paired end reads. *De novo* assembly, mapping and variant calling were performed as described previously⁵⁴, except that mapping was to *S. agalactiae* reference genome 2603 V/R (NC_004116.1). Sequence quality was assessed using various metrics (per cent reads mapped to the reference genome, per cent reference positions called, contig number, total contig length). Sequence data showing poor quality metrics were excluded from further analysis, and where practicable the corresponding samples were re-isolated, re-grouped and re-sequenced (if re-grouping confirmed the isolate as GBS).

We allocated serotypes on the basis of BLASTn comparisons by assessing the sequence similarity of *de novo* assemblies with the capsular locus regions of each of the ten known GBS serotypes. We validated this method internally ($\kappa = 0.92$)⁵⁵. STs were also assigned *in silico* using BLASTn with *de novo* assemblies. Novel STs were submitted to pubmlst.org for assignment. Phylogenetic analysis was performed separately for each clonal complex using RAxML version 8.1.16, with an alignment consisting of all variable sites from mapping to the 2603 V/R reference, padded to the length of the reference with invariant sites of the same GC content as the original data. Recombination was detected using ClonalFrameML⁵⁶ and we present the resultant phylogenies with recombinant regions removed. To partition the isolates according to previously described clonal complexes, we first reconstructed a single RAxML phylogeny with all isolates. The resulting tree was then visually partitioned on long, deep branches, which effectively corresponded to previously described clonal complexes, but enabled us to include all STs. We therefore used this partitioning as our definition of the clonal complexes. Using this definition, each ST belongs to a single clonal complex and each clonal complex is monophyletic (Supplementary Fig. 6), indicating that partitioning by clonal complex remains appropriate when whole-genome data are taken into account.

Pairwise comparison of SNV differences from mapped data was used to examine maternal and newborn paired GBS isolates, and possible transmission of GBS between mothers was investigated via these differences and epidemiological links in time and place (through delivery in KCH) or residence (distance between household locations in KHDSS).

Statistical analysis. We used Stata (version 13.1) for statistical analyses. We used the first principal component from a set of household assets as a proxy for socio-economic status (SES)⁵⁷. Multiple imputation with chained equations (Stata mi) was used to impute missing data on potential risk factors (<15% per variable; 50 imputations). Continuous variables were checked for normality and transformation was not required. We used natural cubic splines to allow for nonlinearity in variable effects in imputation models. Imputations were done separately by maternal GBS status so that interactions could be examined in the analyses of adverse newborn outcomes. The same imputation was used for both analyses; by imputing separately for GBS colonization there are fewer assumptions than if it was fitted as a covariate (this allows variances of continuous imputed variables to differ according to GBS colonization and the associations between two imputed variables can be stronger in one group).

We built multivariable logistic regression models using complete-case and imputed data sets (combined using Rubin's rules) to examine risk factors for maternal GBS colonization using robust variances reflecting clustering by site. We included nonlinearity in continuous variables via natural cubic splines, with factors categorized at quartiles for the presentation of final models. Risk factors with $P < 0.1$ in univariable models were included in a multivariable model, and final independent predictors were identified using backwards elimination (exit $P > 0.1$). We assessed whether risk factors for maternal GBS colonization were associated with ST17 and CC17 colonization in mothers who were GBS colonized using the same process, for complete cases only.

We used the imputed data set in multivariable regression analyses to examine whether maternal GBS colonization was associated with gestational length, birthweight, possible serious bacterial infection, stillbirth or perinatal mortality. We included pre-specified confounders (age, parity, sex (of newborn), maternal education, SES, nutritional status, HIV status, obstetric complication and multiple delivery) and tested for interaction with GBS colonization from prolonged rupture of membranes (PROM, >18 h), maternal fever (>37.5 °C) or urinary tract infection (leukocytes and nitrites present). We included these terms in multivariable models if there was evidence of interaction at the $P < 0.1$ level.

We estimated the odds of isolating GBS from cord blood in all stillbirths, then ante-partum and intra-partum stillbirths, compared to live births. We estimated the incidence of GBS-associated stillbirth and neonatal disease using denominators of facility births and community births, for residents of KHDSS⁵¹.

Ethics. The study protocol was approved by KEMRI Ethical Review Committee (SSC/ERC 2030) and the Oxford Tropical Research Ethics Committee (53-11) (clinicaltrials.gov NCT01757041).

Accession codes. Sequence data have been submitted to the NCBI Sequence Read Archive under BioProject PRJNA315969. Individual accession numbers are provided in Supplementary Table 17 (BioProject PRJNA315969).

Received 8 November 2015; accepted 16 April 2016;
published 23 May 2016

References

- Liu, L. *et al.* Global, regional, and national causes of child mortality in 2000–13, with projections to inform post-2015 priorities: an updated systematic analysis. *Lancet* **385**, 430–440 (2014).
- Goldenberg, R. L., McClure, E. M., Saleem, S. & Reddy, U. M. Infection-related stillbirths. *Lancet* **375**, 1482–1490 (2010).
- Nan, C. *et al.* Maternal group B Streptococcus-related stillbirth: a systematic review. *BJOG* **122**, 1437–1445 (2015).
- Valkenburg-van den Berg, A. W., Sprij, A. J., Dekker, F. W., Dorr, P. J. & Kanhai, H. H. Association between colonization with Group B Streptococcus and preterm delivery: a systematic review. *Acta Obstet. Gynecol. Scand.* **88**, 958–967 (2009).
- Tann, C. J. *et al.* Prevalence of bloodstream pathogens is higher in neonatal encephalopathy cases vs. controls using a novel panel of real-time PCR assays. *PLoS ONE* **9**, e97259 (2014).
- Baker, C. J., Barrett, F. F., Gordon, R. C. & Yow, M. D. Suppurative meningitis due to streptococci of Lancefield group B: a study of 33 infants. *J. Pediatr.* **82**, 724–729 (1973).
- Schrag, S. *et al.* Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis. *N. Engl. J. Med.* **342**, 15–20 (2000).
- Cutland, C. *et al.* (PoPS Trial Team). Chlorhexidine maternal-vaginal and neonate body wipes in sepsis and vertical transmission of pathogenic bacteria in South Africa: a randomised, controlled trial. *Lancet* **374**, 1909–1916 (2009).
- Heyderman, R. S. *et al.* Group B Streptococcus vaccination in pregnant women with or without HIV in Africa: a non-randomised phase 2, open-label, multicentre trial. *Lancet Infect. Dis.* **16**, 546–555 (2016).
- Mullard, A. Making way for maternal immunization. *Nature Rev. Drug Discov.* **15**, 3–4 (2015).
- Barcaite, E. *et al.* Prevalence of maternal group B streptococcal colonisation in European countries. *Acta Obstet. Gynecol. Scand.* **87**, 260–271 (2008).
- Schuchat, A. & Wenger, J. D. Epidemiology of group B streptococcal disease. Risk factors, prevention strategies, and vaccine development. *Epidemiol. Rev.* **16**, 374–402 (1994).
- Anthony, B. F., Okada, D. M. & Hobel, C. J. Epidemiology of group B Streptococcus: longitudinal observations during pregnancy. *J. Infect. Dis.* **137**, 524–530 (1978).
- Regan, J. A., Klebanoff, M. A. & Nugent, R. P. The epidemiology of group B streptococcal colonization in pregnancy. Vaginal Infections and Prematurity Study Group. *Obstet. Gynecol.* **77**, 604–610 (1991).
- Shah, M., Aziz, N., Leva, N. & Cohan, D. Group B Streptococcus colonization by HIV status in pregnant women: prevalence and risk factors. *J. Womens Health* **20**, 1737–1741 (2011).
- Stapleton, R. D., Kahn, J. M., Evans, L. E., Critchlow, C. W. & Gardella, C. M. Risk factors for group B streptococcal genitourinary tract colonization in pregnant women. *Obstet. Gynecol.* **106**, 1246–1252 (2005).
- Cutland, C. L. *et al.* Maternal HIV infection and vertical transmission of pathogenic bacteria. *Pediatrics* **130**, e581–e590 (2012).
- Gray, K. J. *et al.* Group B Streptococcus and HIV infection in pregnant women, Malawi, 2008–2010. *Emerg. Infect. Dis.* **17**, 1932–1935 (2011).
- Mavenyengwa, R. T. *et al.* Group B Streptococcus colonization during pregnancy and maternal–fetal transmission in Zimbabwe. *Acta Obstet. Gynecol. Scand.* **89**, 250–255 (2010).
- Madzivhandila, M. *et al.* Serotype distribution and invasive potential of group B Streptococcus isolates causing disease in infants and colonizing maternal–newborn dyads. *PLoS ONE* **6**, e17861 (2011).
- Moyo, S. R., Mudzori, J., Tswana, S. A. & Maeland, J. A. Prevalence, capsular type distribution, anthropometric and obstetric factors of group B Streptococcus (*Streptococcus agalactiae*) colonization in pregnancy. *Cent. Afr. J. Med.* **46**, 115–120 (2000).
- Mosabi, J. M., Arimi, S. M. & Kang'ethe, E. K. Isolation and characterization of group B Streptococci from human and bovine sources within and around Nairobi. *Epidemiol. Infect.* **118**, 215–220 (1997).
- Edmond, K. M. *et al.* Group B streptococcal disease in infants aged younger than 3 months: systematic review and meta-analysis. *Lancet* **379**, 547–556 (2012).
- The WHO Young Infants Study Group. Bacterial etiology of serious infections in young infants in developing countries: results of a multicentre study. *Pediatr. Infect. Dis.* **18**, S17–S22 (1999).
- Hamer, D. H. *et al.* Etiology of bacteremia in young infants in six countries. *Pediatr. Infect. Dis. J.* **34**, e1–e8 (2015).
- Berkley, J. *et al.* Bacteremia among children admitted to a rural hospital in Kenya. *N. Engl. J. Med.* **352**, 39–47 (2005).

27. Gray, K., Bennett, S. L., French, N., Phiri, A. J. & Graham, S. M. Invasive group B streptococcal infections in infants, Malawi. *Emerg. Infect. Dis.* **13**, 223–229 (2007).
28. Ojukwu J. U., Abonyi, L. E., Ugwu, J. & Orji, I. K. Neonatal septicemia in high risk babies in South-Eastern Nigeria. *J. Perinat. Med.* **34**, 166–172 (2006).
29. Madhi, S. *et al.* High burden of invasive *Streptococcus agalactiae* in South African infants. *Ann. Trop. Paediatr.* **23**, 15–23 (2003).
30. Folgosa, E. *et al.* A case control study of chorioamnionic infection and histological chorioamnionitis in stillbirth. *APMIS* **105**, 329–336 (1997).
31. Moyo, S. R. *et al.* Stillbirths and intrauterine infection, histologic chorioamnionitis and microbiological findings. *Int. J. Gynaecol. Obstet.* **54**, 115–123 (1996).
32. Da Cunha, V. *et al.* *Streptococcus agalactiae* clones infecting humans were selected and fixed through the extensive use of tetracycline. *Nature Commun.* **5**, 4544 (2014).
33. Sorensen, U. B., Poulsen, K., Ghezzi, C., Margarit, I. & Kilian, M. Emergence and global dissemination of host-specific *Streptococcus agalactiae* clones. *mBio* **1**, e-00178-10 (2010).
34. Bekker, V., Bijlsma, M. W., van de Beek, D., Kuijpers, T. W. & van der Ende, A. Incidence of invasive group B streptococcal disease and pathogen genotype distribution in newborn babies in the Netherlands over 25 years: a nationwide surveillance study. *Lancet Infect. Dis.* **14**, 1083–1089 (2014).
35. Brochet, M., Couve, E., Bercion, R., Sire, J. M. & Glaser, P. Population structure of human isolates of *Streptococcus agalactiae* from Dakar and Bangui. *J. Clin. Microbiol.* **47**, 800–803 (2009).
36. Mahmood, Y. S., Klaas, I. C., Katholm, J., Lutton, M. & Zadoks, R. N. Molecular epidemiology and strain-specific characteristics of *Streptococcus agalactiae* at the herd and cow level. *J. Dairy Sci.* **98**, 6913–6924 (2015).
37. Rato, M. G. *et al.* Antimicrobial resistance and molecular epidemiology of streptococci from bovine mastitis. *Vet. Microbiol.* **161**, 286–294 (2013).
38. Springman, A. C. *et al.* Selection, recombination, and virulence gene diversity among group B streptococcal genotypes. *J. Bacteriol.* **191**, 5419–5427 (2009).
39. Ravel, J. *et al.* Vaginal microbiome of reproductive-age women. *Proc. Natl Acad. Sci. USA* **108**(Suppl. 1), 4680–4687 (2011).
40. Cutland, C. L. *et al.* Increased risk for group B *Streptococcus* sepsis in young infants exposed to HIV, Soweto, South Africa, 2004–2008. *Emerg. Infect. Dis.* **21**, 638–645 (2015).
41. Le Doare, K. *et al.* Anti-group B *Streptococcus* antibody in infants born to mothers with human immunodeficiency virus (HIV) infection. *Vaccine* **33**, 621–627 (2015).
42. Dangor, Z. *et al.* HIV-1 is associated with lower Group B *Streptococcus* capsular and surface-protein IgG antibody levels and reduced transplacental antibody transfer in pregnant women. *J. Infect. Dis.* **212**, 453–462 (2015).
43. Johri, A. K. *et al.* Group B *Streptococcus*: global incidence and vaccine development. *Nature Rev. Microbiol.* **4**, 932–942 (2006).
44. D'Urzo, N. *et al.* Acidic pH strongly enhances *in vitro* biofilm formation by a subset of hypervirulent ST17 *Streptococcus agalactiae* strains. *Appl. Environ. Microbiol.* **80**, 2176–2185 (2014).
45. Manning, S. *et al.* Association of Group B *Streptococcus* colonization and bovine exposure: a prospective cross-sectional cohort study. *PLoS ONE* **5**, e8795 (2010).
46. Huber, C. A., McOdimba, F., Pflueger, V., Daubenberger, C. A. & Revathi, G. Characterization of invasive and colonizing isolates of *Streptococcus agalactiae* in East African adults. *J. Clin. Microbiol.* **49**, 3652–3655 (2011).
47. Almeida, A. *et al.* Whole-genome comparison uncovers genomic mutations between Group B Streptococci sampled from infected newborns and their mothers. *J. Bacteriol.* **197**, 3354–3366 (2015).
48. Le Doare, K. *et al.* Risk factors for Group B *Streptococcus* colonisation and disease in Gambian women and their infants. *J. Infect.* **72**, 283–294 (2016).
49. Nasri, K., Chehrei, A. & Manavi, M. S. Evaluation of vaginal group B streptococcal culture results after digital vaginal examination and its pattern of antibiotic resistance in pregnant women. *Iran. J. Reprod. Med.* **11**, 999–1004 (2013).
50. Bellais, S. *et al.* Capsular switching in group B *Streptococcus* CC17 hypervirulent clone: a future challenge for polysaccharide vaccine development. *J. Infect. Dis.* **206**, 1745–1752 (2012).
51. Scott, J. A. *et al.* Profile: the Kilifi Health and Demographic Surveillance System (KHDSS). *Int. J. Epidemiol.* **41**, 650–657 (2012).
52. Schrag, S. J. & Verani, J. R. Intrapartum antibiotic prophylaxis for the prevention of perinatal group B streptococcal disease: experience in the United States and implications for a potential group B streptococcal vaccine. *Vaccine* **31**(Suppl. 4), D20–D26 (2013).
53. Stoner, K., Rabe, L. K. & Hillier, S. L. Effect of transport time, temperature, and concentration on the survival of Group B streptococci in Amies transport medium. *J. Clin. Microbiol.* **42**, 5385–5387 (2004).
54. Mathers, A. J. *et al.* *Klebsiella pneumoniae* carbapenemase (KPC)-producing *K. pneumoniae* at a single institution: insights into endemicity from whole-genome sequencing. *Antimicrob. Agents Chemother.* **59**, 1656–1663 (2015).
55. Sheppard, A. E. *et al.* Capsular typing method for *Streptococcus agalactiae* using whole genome sequence data. *J. Clin. Microbiol.* **54**, 1388–1390 (2016).
56. Didelot, X. & Wilson, D. J. ClonalFrameML: efficient inference of recombination in whole bacterial genomes. *PLoS Comput Biol.* **11**, e1004041 (2015).
57. Filmer, D. & Pritchett, L. H. Estimating wealth effects without expenditure data—or tears: an application to educational enrollments in states of India. *Demography* **38**, 115–132 (2001).

Acknowledgements

The authors acknowledge The Wellcome Trust (093804) for funding this study. A.C.S. and J.A.B. are funded by fellowships from the Wellcome Trust (www.wellcome.ac.uk; 093804 and 098532). D.W.C. is an NIHR (UK) Senior Investigator. D.W.C., A.E.S. and A.S.W. received funding from the Health Innovation Challenge Fund (a parallel funding partnership between the Department of Health and the Wellcome Trust; HICF-T5-358 and WT098615/Z/12/Z); the UK Clinical Research Collaboration (a parallel funding partnership between the Medical Research Council (G0800778), the Biotechnology and Biological Sciences Research Council and the Wellcome Trust (087646/Z/08/Z)) and the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre. S.S. receives funding from the National Center for Immunization and Respiratory Diseases, US Centers for Disease Control and Prevention. The Wellcome Trust (core grant 077092) and the Bill and Melinda Gates Foundation fund paediatric and maternal research at KEMRI–Wellcome Trust Programme.

The authors thank all the fieldworkers and clinical staff who contributed to this work in Kilifi County Hospital (formerly Kilifi District Hospital), Coast Provincial General Hospital, Bamba sub-district Hospital and Ganze Health Facility, as well as all the participants in this study. Whole-genome sequencing was undertaken at The Wellcome Trust Centre for Human Genetics, University of Oxford, and the authors thank the library and sequencing teams. Initial pre-processing of raw sequence data was done using a data-processing pipeline developed by the Department of Statistics, University of Oxford. Surveillance at Kilifi County Hospital was undertaken at the Kenya Medical Research Institute/Wellcome Trust Research Programme, and the authors thank all those involved. This study is published with the permission of the Director of the Kenya Medical Research Institute.

Author contributions

The study was conceived and designed by A.C.S., A.C.K., S.C.M., C.J., B.T., S.J.S., S.H.K., G.F., D.W.C. and J.A.B. Data were acquired, analysed and/or interpreted by A.C.S., A.C.K., A.E.S., H.C.B., J.L., E.A., Sa.M., S.C.M., K.A., A.V., A.G., P.M., L.W., H.M., D.M., M.S., B.K., N.M., E.M., D.M., V.B., M.S., M.O., A.S.W., S.J.S., G.F., D.W.C. and J.A.B. Administrative or technical support was provided by A.E.S., Sa.M., S.C.M., K.A., A.V., A.G., P.M., L.W., C.J., N.M., B.T., E.M., D.M., V.B., M.S., M.O., A.S.W., S.H.K., G.F., W.D.C. and J.A.B. Statistical analysis was done by A.C.S., with advice from G.F., A.S.W. and J.A.B. Phylogenetics were performed by A.E.S. with A.C.S. The first draft was written by A.C.S. All authors reviewed the manuscript.

Additional information

Supplementary information is available [online](http://www.nature.com/reprints). Reprints and permissions information is available online at www.nature.com/reprints. Correspondence and requests for materials should be addressed to A.C.S.

Competing interests

The authors declare no competing financial interests.